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Background: Biological pathways are important for understanding biological mechanisms. Thus, finding important
pathways that underlie biological problems helps researchers to focus on the most relevant sets of genes. Pathways
resemble networks with complicated structures, but most of the existing pathway enrichment tools ignore
topological information embedded within pathways, which limits their applicability.
Results: A systematic and extensible pathway enrichment method in which nodes are weighted by network
centrality was proposed. We demonstrate how choice of pathway structure and centrality measurement, as well as
the presence of key genes, affects pathway significance. We emphasize two improvements of our method over
current methods. First, allowing for the diversity of genes’ characters and the difficulty of covering gene importance
from all aspects, we set centrality as an optional parameter in the model. Second, nodes rather than genes form
the basic unit of pathways, such that one node can be composed of several genes and one gene may reside in
different nodes. By comparing our methodology to the original enrichment method using both simulation data
and real-world data, we demonstrate the efficacy of our method in finding new pathways from biological
perspective.
Conclusions: Our method can benefit the systematic analysis of biological pathways and help to extract more
meaningful information from gene expression data. The algorithm has been implemented as an R package CePa,
and also a web-based version of CePa is provided.
Keywords: Pathway enrichment, Biological network, Centrality, Gene expression dataBackground
As omics and high throughput technology continues to
develop, researchers can increasingly understand bio-
logical phenomena at the systems level; that is, can elu-
cidate the complicated interactions between genes and
molecules responsible for biological functions [1].
Microarray technology has been widely used to measure
gene expression profiles and has produced huge
amounts of data for biological analysis [2]. However,
traditional single gene analysis tells us little about the
cooperative roles of genes in real biological systems.
New challenges for microarray data analysis are to find
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reproduction in any medium, provided the orrelated genes. Biological pathways are sets of genes or
molecules that act together by chemical reactions, mol-
ecule modifications or signalling transduction to carry
out such functions [3]. Since pathways are essentially
integrated circuits that actualize specified biological pro-
cesses, perturbation of pathways may be harmful to
regular biological systems. Thus, finding biologically im-
portant pathways can assist researchers in identifying
sets of genes responsible for essential functions. Cur-
rently, amount of tools are available to identify which
pathways are significantly influenced based on the tran-
scription level change of member genes [4,5]. In other
words, they identify pathways where differentially
expressed genes are enriched.
Since a pathway can be denoted as a set of genes,
pathway enrichment belongs to a more general category
of methods termed gene set enrichment. Two mainThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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resentation analysis (ORA) and gene set analysis (GSA)
[6]. The former only focuses on the number of differen-
tial genes in the pathway, while the latter incorporates
the entire gene expression from microarray datasets. In
fact, ORA is a special case of GSA, utilizing a binary
transformation of gene expression values. In standard
ORA, the correlations between genes within the pathway
and those that are differentially expressed are evaluated
by Fisher’s exact test or chi-square test, in form of a
2 × 2 contingency table [7]. The most popular ORA on-
line tool in current use is DAVID [8], which supports a
variety of species and gene identifiers. For researchers fa-
miliar with the R statistical environment, the GOstats
package [9] is a highly recommended ORA analysis tool.
GSA methods are implemented via either a univariate or
a multivariate procedure [6]. In univariate analysis, gene
level statistics are initially calculated from fold changes
or statistical tests (e.g., t-test). These statistics are then
combined into a pathway level statistic by summation or
averaging [6]. GSEA [10] is a widely used univariate tool
that utilizes a weighted Kolmogorov-Smirnov test to
measure the degree of differential expression of a gene
set by calculating a running sum from the top of a
ranked gene list. Multivariate analysis considers the cor-
relations between genes in the pathway and calculates
the pathway level statistic directly from the expression
value matrix using Hotelling’sT2 test [11] or MANOVA
models [12]. Besides these standard models, extended
models of GSA exist. For example, GSCA (Gene Set Co-
Expression Analysis) [13] aims to identify gene sets
whose members have different co-expression structures
between phenotypes; ROAST [14] uses a Monte-Carlo
simulation for multivariate regression which is applicable
to diverse experimental designs; GGEA (Gene Graph
Enrichment Analysis) [15] evaluates gene sets as Petri
networks constructed from an a priori established gene
regulatory network. Further studies have focused on the
methodology issues of gene set enrichment analysis,
such as evaluating the power of different statistical mod-
els [6,16], generating null distributions of gene set scores
[17,18], and overlapping of gene sets [19-21]. The ap-
proach of gene set enrichment analysis is also applicable
to a broad range of systems-biology-related fields, in-
cluding functional network module analysis [22] and
microRNA target prediction [23,24].
Current enrichment methods are limited for pathway
analysis because they treat genes identical in pathways.
Rather than comprising a list of genes, a pathway identi-
fies how member genes interact with each other. Clearly,
perturbation on a key gene will make more considerable
effect for the pathway than on an insignificant gene.
Since a pathway is represented as a network with nodes
and edges, its topology is essential for evaluating theimportance of the pathway. To date, few pathway en-
richment studies have incorporated any topological in-
formation. Gao et al. [25] designed a pathway score in
which the values of all connected gene pairs are
summed, where the value of a gene pair is obtained by
multiplying the absolute normalized expression values of
the paired genes. Hung et al. [26] defined a value for
each gene based on the closest correlated neighbor
genes, and assumed this value as the weight of the
Kolmogorov-Smirnov test in GSEA procedure [10] for
each pathway. Drăghici et al. [27] introduced a topology
term into the scoring function, reflecting that the im-
portance of genes is enhanced if they in turn influence
important downstream genes. Thomas et al. [28]
assigned larger weights to upstream and downstream
pathway genes, and to genes having high connectivity,
and then integrated into the maxmean statistics [29].
Currently available methods determine the importance
of genes in the pathway by a single measure. However,
because of the complexity of biological pathways and
the varying characteristics of genes, such single-measure
quantitation cannot fully capture the properties of differ-
ent genes on biological environment. Thus, a model that
comprehensively integrates both enrichment and top-
ology information is urgently required.
Here, we propose a general, systematic and extensible
enrichment methodology by which to find significant
pathways using topology information. Two improve-
ments of our method over current methods are appar-
ent. First, given the diversity of genes’ characteristics and
the difficulties of covering gene importance from all
angles, we do not assume a fixed measurement for each
gene but allow the user to specify the method by which
network nodes will be weighted, as an optional param-
eter in the model. This feature enables researchers to as-
sess gene importance from a perspective relevant to
their particular biological problem. In our model, the
importance of genes in pathways is assessed by network
centralities. In graph theory, centrality provides a means
of ranking nodes based on network structure. Different
centrality measurements assign importance to nodes
from different aspects. Degree centrality quantifies the
number of neighbours to which a node directly con-
nects, while betweenness defines the number of informa-
tion streams passing through a given node. Generally
speaking, large centrality values are assigned to central
nodes in the network. Nodes representing metabolites,
proteins or genes with high centralities are essential for
maintaining biological networks in steady state [30,31].
Moreover, the relevance of a particular centrality meas-
urement may vary according to the biological role of the
pathway [32,33]. Choice of centrality measurement
depends on the types of genes considered important in
the pathway. Second, nodes rather than genes are taken
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the regular biological functions in significant pathways
are usually altered where abnormal pathway states arise
from abnormal internal node states. We note that path-
way nodes may represent not only single genes, but also
complexes and protein families. For a complex compris-
ing more than one gene, if one member gene has been
altered, the function of the whole complex is disrupted.
On the other hand, a single gene may reside in multiple
complexes; if this gene loses its function, all of its com-
plexes will be influenced. Therefore a mapping proced-
ure from genes to pathway nodes is applied in our
model. The pathway nodes further include non-gene
nodes such as microRNAs and compounds, which also
contribute to the topology of the pathway. Hence, all
types of nodes are retained in our pathway analysis.
In this article, the original pathway enrichment
method is extended by assigning network centralities as
node weights, and nodes are mapped from differentially
expressed genes in pathways. The model is flexible in
that it can readily accommodate available gene set en-
richment methods and various topological measure-
ments. Through a simulation study, we demonstrate
how pathway significance depends on network structure
and choice of centrality measurement. In the analysis of
liver cancer data set, our model identified relevant bio-
logical processes which were bypassed using existing
methods. We also demonstrate how key genes affect the
significance of pathways directly underlying biological
processes.
Results and discussion
Because ORA methodology is easily implemented and
rapidly executed, it is favored over GSA in applications
[8]. Therefore, we focus mainly on the centrality-based
extension of ORA, while the extension of GSA will be
discussed briefly at the end of this article.
Mapping genes to nodes
Since a pathway represents as a network, the basic unit
of the network (the node) is not always a single gene. In
real biological pathways, the nodes can also represent
complexes or protein families. Moreover, the product of
a particular gene may be incorporated into different
complexes to serve different functions. Such diverse
roles of gene products are ignored by traditional ORA
methods, possibly leading to erroneous interpretations.
Abnormal node states are expected to contribute to the
abnormal states of pathways. As previously mentioned,
the function of a multi-gene complex is affected by alter-
ation of any one gene in the complex, while alteration of
a multi-complex gene influences all of the complexes in
which the gene resides. Merely counting genes in path-
ways cannot reflect these different types of roles playedby different genes. In a real-world pathway catalogue, a
node typically comprises two or more genes, and some
genes locate in multiple complexes or families. Among
pathways in the NCI-Nature catalogue of Pathway Inter-
action Database (PID) [34], 58.6% of nodes comprise
more than one gene while 47.2% of genes reside in mul-
tiple nodes (Figure 1A, 1B). Compounds and micro-
RNAs can also form pathway nodes. Although the
changing quantity of these entities is not captured by
typical microarray experiments, they may contribute sig-
nificantly to pathway regulation. Therefore, these types
of nodes cannot be neglected in topological pathway
analysis. For the above reasons, the number of genes
involved in a biological pathway does not correspond to
the number of nodes in the pathway. Figure 1C shows
how node count varies with gene count in pathways
extracted from PID. Therefore, in our analysis we map
genes to the pathway nodes and assume the node as the
basic pathway unit. In this way, if any member of a com-
plex or family is differentially expressed, the node repre-
senting the complex or family is differentially affected.
We consider that nodes representing protein coding
genes, compounds and microRNAs are all legitimate
regulators of pathways.
Pathway score
In any pathway enrichment framework, the significance
of a pathway is evaluated by a pathway-level statistic.
For example, in ORA, the pathway-level statistic is the
number of differentially expressed genes in a pathway.
To account for the varying positions of genes within
pathways, we introduce a new statistic (here called the
pathway score), defined as the summation of the weight





di ¼ 1 differentially affected0 else

ð2Þ
where s is the pathway score, wi is the weight of the i
th
node (reflecting the importance of the node), n is the
number of nodes in the pathway, and di identifies
whether the ith node is differentially affected. The path-
way score is the aggregate of two components, the
weight and the number of differential nodes. Therefore,
if a node has larger weight, i.e. is more important, it
more strongly determines whether the pathway is signifi-
cant. On the other hand, large numbers of differential
nodes also increase the pathway score. Consequently, a
significant pathway may contain a few highly important












 Distribution of the number
of member genes in each node

















 Distribution of the number
of nodes in which a single gene resides













 Relationship between node count










Figure 1 Meta-analysis of the pathway catalogue. A) Distribution of the number of member genes in each node; B) Distribution of the
number of nodes in which a single gene resides; C) Relationship between node count and gene count in biological pathways. The pathways are
derived from Pathway Interaction Database, NCI-Nature catalogue. For figure A and B, points are log-scaled on the Y-axis.
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inition of w is general and the weight can be assigned
any value the researcher considers appropriate. Note
that when wi= 1 for all i, s is simply the number of dif-
ferential nodes in the pathway. We refer to this condi-
tion as the equal weight condition in the following
section.
Centrality measurements
The most important information in pathways comprises
the complicated interactions between genes that govern
the transmission of biological signals through networks.
Since pathways present as networks, it is natural to de-
fine the weight w from topological information. In exist-
ing methods using topological information, various
aspects of gene importance are assigned fixed values. It
is noteworthy that, because genes play different roles in
biological pathways, it is difficult to design measure-
ments that cover the entire spectrum of a gene’s func-
tion. Instead of designing single measurements, we
compute various topological measurements that meas-
ure the importance of genes from different aspects.
Since different measurements relate to different bio-
logical functions, the best practice is to try every choice
in the search for significant pathways.
Here, we identify central nodes in pathways using net-
work centrality. Recall from the Background section that
centrality in graph theory is a means of ranking nodes
according to network structure. Two frequently-used
centralities, degree and shortest path betweenness (or
more concisely, betweenness), are selected as candidate
measurements. Since pathways are directed networks,
degree centrality is denoted as in-degree and out-degree.In biological networks, in-degree refers to the number of
upstream genes directly acting on a given gene, while
out-degree refers to the number of downstream genes
directly acted upon by the gene. As previously men-
tioned, betweenness assesses the amount of information
streaming through a given node in the network. These
two centralities are broadly used in biological network
analysis [31,35].
To measure the importance of nodes in the network
from different aspects, we define an additional centrality:
largest reach. The largest reach centrality is based on the
shortest path between two nodes and is affected by all
the other nodes in the network. The largest reach cen-
trality determines how far a node can send or receive in-
formation within the network. It is defined as the largest
length of the shortest paths to all the other nodes in the
network. Since information is always transmitted se-
quentially in biological pathways, the largest reach cen-
trality can reflect whether nodes stay in the upstream or
downstream part of the pathway. In a directed network,
the largest reach is denoted as in-largest reach and out-
largest reach.
Other centralities, besides those described above, can
also be considered. For instance, the closeness centrality
computes the time required to spread information from
one node to all other nodes. The eccentricity centrality
determines whether a node resides in the center of the
network and whether the distribution of nodes around
the central node is symmetric. The stress centrality mea-
sures the extent to which a node can hold network com-
munications. The eigenvector centrality measures the
importance of a node based on its connections to other
high-scoring nodes in the network (which contribute
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tralities closely related to the eigenvector are Katz’s Sta-
tus Index and PageRank. For more details on this
subject, readers may refer to [32,33,36].
Simulation study
A novel gene list and a novel pathway are generated in
the simulation study. In the pathway, we assume that
every node corresponds to a single gene. The contin-
gency table for ORA is listed in Table 1. The p-value of
the pathway (1.36 × 10−5 by Fisher’s exact test, one sided)
is constant and independent of pathway structure.
The structure of the pathway is generated as random
networks. Two representative random network models,
Erdös-Rényi model [37] (abbreviated to ER) and
Barabási-Albert model [38] (abbreviated to BA), are
selected. These models are the basic random network
models in graph theory but their network structures dif-
fer. We generate ER random networks as follows: 1)
Each pair of nodes has the same probability (1/n) to be
connected, where n is the number of nodes in the path-
way; 2) Each connection can choose a direction with
equal probability (p= 0.5). The BA random network is
generated as follows: 1) The probability that a node will
make a new connection is proportional to its degree; 2)
Each connection can choose a direction with equal prob-
ability (p= 0.5). In the ER model, node degree follows a
binomial distribution; while in BA model it follows a
power law distribution. In the BA model, the majority of
nodes have few neighbors while a small minority holds
most connections in the network. Examples of ER and
BA random networks can be found in Additional file 1.
The structure of the pathway was generated for 1000
times, and 40 differential nodes were randomly selected
from each simulated network. For each simulated net-
work, we calculate the significant of the pathway. Values
of in-degree, out-degree, betweenness, in-largest reach,
out-largest reach centralities, as well as the equal weight
condition, are compared between our method and trad-
itional ORA. Note that since every node corresponds to
a single gene, the equal weight condition approximates
to the hypergeometric distribution, on which traditional
ORA is based [7].
Since the pathway score is computed from a list of dif-
ferential nodes, we measure the approximateTable 1 2× 2 contingency table for ORA
In the pathway Else Total
Differential 40 960 1000
Else 160 8840 9000
Total 200 9800 10000
The simulated microarray contains 10000 genes of which 1000 genes are
differentially expressed. The novel pathway contains 200 genes of which 40
are differential genes.distribution of the differential nodes’ centrality in each
simulation by four values: maximum, median, minimum
and 75th quartile. From these four values, the effect of
the differential nodes’ centralities on the final pathway
score can be estimated. Figure 2 illustrates p-values and
distribution of centralities of differential nodes in each
simulation under different centrality measurements. The
proportions of the pathway with p-values≤ 0.01 are listed
in Table 2. Clearly, the significance of the pathway is lost
when centrality is used as a weighting factor, and levels
of pathway significance depend on network structure
and type of centrality measure. For example, in an ER-
generated network structure in which nodes are
weighted by in-degree, the proportion of being signifi-
cant for the pathway is 57.4% out of 1000 simulations.
When using degree (in and out) as the weight, the ER
model outputs a larger proportion of significant path-
ways than does the BA model. In BA, a small minority
of important nodes (measured by degree) dominates the
pathway; hence, if differential nodes are randomly picked
from a BA network, the probability of selecting those
nodes which yield large pathway scores is low. The ma-
jority of trials, therefore, generate insignificant pathways.
It is observed that maximum largest reaches (in and
out) from both ER and BA networks are similar (around
10; see Figure 2), but the median values and the 75th
quartile of largest reach in the BA-generated network
exceed those of the ER-generated network, implying that
the distribution of largest reach in BA model is right
shifted relative to that of the ER model (The histograms
of the largest reach in both models can be found in
Additional file 2). As a result, when using largest reach
as weight, the BA model produces a higher proportion
of significant pathways than does the ER model. This is
due to the presence of central hub nodes in the BA
model, which ensure robust information transmission
and are thus more likely to score high largest reach
values.
From the simulation study, we observe that although
the number of differential nodes in a pathway is significant
by Fisher’s exact test (or by its approximation, the equal
weight condition), the pathway will not be significantly
affected if these genes hold less important positions in the
pathway. The level of significance is affected by both cen-
trality measurements and network structure. If researchers
consider that nodes with large degree will be more import-
ant, without considering the network topology, traditional
ORA would yield large false positives. In the current simu-
lation study, the proportion of significant pathway under
ORA is expected to be 100%; but, when the structure of
the pathway is assembled by the ER model and assessed
by degree centrality, there are only 57.4% significant path-
ways from 1000 simulations. It means there would be
42.6% false positives from above perspective.
Figure 2 (See legend on next page.)
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Figure 2 P-values and centrality distributions of pathways with different random network structures under different centrality
measurements. Pathway topologies are generated from (A) Erdös-Rényi model and (B) Barabási-Albert model. Comparisons are made between
in-degree, out-degree, betweenness, in-largest reach, out-largest reach centralities, as well as the equal weight condition. Each plot represents the
distribution of differential nodes centralities in each simulation, assessed by maximum value, the 75th quartile, median value and minimum value.
All data are ordered by p-values on the X-axis. Points in the figure are randomly shifted by small intervals for ease of visualization.
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We next assess the influence of the key nodes in the evalu-
ation of pathway significance. For the same novel gene list
and novel pathway as were used in the simulation study,
the number of differential nodes in the pathway is varied
from 1 to 100. The pathway structures are generated from
the BA model with no directions, and degree is used as the
centrality measure. Differential nodes may be integrated
into the pathway via two approaches; 1) from largest to
smallest degree, and 2) from smallest to largest degree.
In the BA model the small number of nodes holding
most connections are the most central nodes, thus they
contribute majorly to the significance of the pathway. The
pathway would be altered if these nodes were differentially
affected. As illustrated in Figure 3, when selecting high-
degree differential nodes, provided that the number of dif-
ferential nodes is 5 or greater, the pathway is highly signifi-
cant (p-value < 0.01). By comparison, pathways generated
from 5 differential nodes by traditional ORA are far from
significant (p-value 1). Applying ORA, the minimum
number of differential nodes required to achieve p-value <
0.01 is 31. On the contrary, if differential nodes in the
pathway are largely of very low degree, many more of
these nodes are required to make the pathway significant.
As shown in Figure 3, at least 90 small-degree differential
nodes must be selected to render the p-value of the path-
way less than 0.01. In conclusion, considering the number
of differential nodes alone cannot fully reflect the signifi-
cance of the pathway. We reiterate that without highlight-
ing these key nodes, researchers are likely to make
erroneous interpretations of biological pathways.
Real-world data analysis
We tested our method on a real microarray dataset
[GEO: GSE22058] [39]. The microarray experimentTable 2 Proportion of pathways with p-values≤0.01 in
simulation study
Centrality ER model BA model




In-largest reach 0.493 0.767
Out-largest reach 0.448 0.745measures mRNA expression changes in liver cancer
tissue and adjacent non-tumour tissue. Following gene
ID matching and duplicated gene merging, 18503 genes
were obtained. The top 2000 most differentially
expressed genes (determined by t-test) comprised our
differential gene list. NCI-Nature pathway catalogue
from Pathway Interaction Database (PID) [34] was used
because it is manually curated and reviewed, and is
highly recommended by the PID database. In-degree,
out-degree, betweenness, in-largest reach and out-largest
reach centrality measurements were applied and com-
pared. In addition, we applied the dataset to equal
weight condition and traditional ORA because the equal
weight condition maps genes to nodes, while traditional
ORA focuses solely on gene number. P-values for path-
ways are calculated from 1000 simulations and the false
discovery rate (FDR) is calculated by Benjamini-
Hochberg (BH) process [40]. Cutoff for FDR is set to
0.05.
Figure 4 illustrates the heatmaps of the FDRs of path-
ways generated under different centrality measurements.
A complete list of p-values and FDRs is tabulated in
Additional file 3 and Additional file 4. Among the 11
pathways for which our method agrees with traditional
ORA using at least one centrality, the PLK pathway,
MET pathway and MAPK pathway are directly related
to liver cancers [41,42]. MAPK pathway is significant
when nodes are weighted by in-largest reach (p-value =
0.001, FDR= 0.025), consistent with expected biological
phenomena. The differential nodes are mainly located in
the downstream of the pathway; that is, transcriptional
factors (e.g. FOS) or cell cycle related factors (e.g. CDK5
and CD5R1), while few of the upstream genes are
included in our differential gene list. As the MAPK path-
way is essentially a cascade of sequential interactions
[43], weighting its nodes by out-largest reach renders it
insignificant, whereas weighting by in-largest reach,
which gives larger weight to the downstream nodes,
marks the pathway as significant (Figure 5). In other
words, if the pathway is rendered significant by in-
largest reach weighting, we can infer that the down-
stream nodes are differentially affected.
Among 8 pathways evaluated as insignificant by trad-
itional ORA but significant by centrality-based methods,
four have been previously linked to liver cancers
[42,44,45]. AP-1 pathway is assessed as insignificant by
Figure 4 Heatmap of FDRs in pathways. A) Pathways evaluated as significant by both traditional ORA and our method for at least one
centrality measure; B) Pathways for which our method disagrees with traditional ORA. In each heatmap, columns are sorted by FDRs calculated
from traditional ORA and rows are sorted through hierarchical clustering. Green and red denote insignificant and highly significant, respectively.













Comparison of p−values influenced by key nodes







pick nodes with high degree first
pick nodes with low degree first
Figure 3 Comparison of p-values influenced by key nodes. Differential nodes, weighted by degree, are selected in two ways: from high to
low degree and from low to high degree. Also, traditional ORA was applied for comparison.
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Figure 5 Summary of MAPK-TRK pathway generated under in-largest reach centrality. A) Distribution of in-largest reach centrality of
differential nodes in the simulated pathway. The distribution of differential nodes centralities in each simulation is assessed by maximum value,
the 75th quartile, median value and minimum value; B) Distribution of in-largest reach centrality of all nodes in the real pathway; C) Histogram of
simulated scores in the pathway; D) Graph view of the pathway where the size of a node is proportional to its centrality value and nodes in red
represent differential nodes. In figures A and B, dots are randomly shifted by small intervals for ease of visualization. In figures A and C, the real
pathway score is marked with a red line.
Gu et al. BMC Systems Biology 2012, 6:56 Page 9 of 13
http://www.biomedcentral.com/1752-0509/6/56traditional ORA because, of the 70 genes involved in the
pathway, only 15 are differential. However, after map-
ping genes to the pathway nodes, we obtain 55 differen-
tial nodes among 114 pathway nodes. Because two key
genes, FOS and JUN [46,47], combine with a host of
other genes to form activated complexes in the pathway,
the mapping procedure increases the number of posi-
tions that these two genes occupy in the network. There-
fore the AP-1 pathway becomes more significant under
equal weight condition than under traditional ORA. As
another example, the VEGF receptor (VEGFA) is a prin-
cipal component in the VEGFR1 and VEGFR2 signaling
pathway. As a membrane protein, VEGFA receives large
quantities of extracellular information and disseminates
it into intracellular proteins [48]. VEGFA requires-
VEGFR2 to form an activated complex, hence the repre-
sentative node possesses high values of both in-degree
and out-degree, and the degree-weighted pathway is ren-
dered significant (p-value = 0.002, FDR= 0.034 for in-degree; p-value = 0.007, FDR= 0.104 for out-degree). On
the other hand, VEGFA itself is not differentially
expressed, but its companion gene VEGFR2 is. Conse-
quently, an abnormal state of the member gene results
in a dysfunctional complex. This type of circumstance,
which cannot be inferred by traditional ORA, empha-
sizes why nodes, rather than genes, should form the
basic units in pathway analysis.
Conclusions
Pathway analysis can assist researchers to understand
biological aberrations at a systems level. The functional-
ity of biological pathways depends upon complex gene
interactions. Therefore, pathway enrichment tools should
highlight genes that play important roles in the pathway
from the view of topology. Here we proposed a systematic
and extensible methodology, which finds significant path-
ways using network centrality to weight the nodes. We
demonstrated that levels of pathway significance depend
Figure 6 Workflow of the centrality-based pathway enrichment analysis. A typical figure on the left illustrates the corresponding step on
the right side. The essential steps are: 1) Obtain a differentially expressed gene list. This list can be compiled using a variety of methods and
sources; 2) Map genes to nodes; 3) Select several centrality measurements and calculate their values; 4) Weighting nodes by centrality, calculate
the pathway-level score; 5) In simulations, repeat steps 1 to 4 for a user-specified number of cycles (1000 cycles were used in the current study)
and generate a null distribution of pathway-level scores; 6) Calculate p-values and display the results summary.
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The method performed favorably when applied to real-
world data.
Centrality can reflects the central nodes in a pathway,
and different centralities assign gene importance from
different aspects. The use of centralities in biological
networks can aid in explaining biological phenomena. In
this work, we demonstrated the advantages of using
multiple centrality measurements to obtain a complete
view of the system. Pathway nodes, rather than genes,
should form the basic units in pathway analysis, since
many genes must aggregate as complexes in order to
function completely. The focus on pathway nodes
accommodates the fact that genes can be members of
complexes or families, or may exist in many complexes.
Finally, it should be noted that a high quality and non-
redundant pathway structure dataset is required. Pro-
jects like BioPAX [49], which aspire to the integration
and exchange of biological pathway data, will greatly as-
sist future pathway analysis.
Our method can reveal new findings that relate to,
and can aid the understanding of, current biologicalproblems. We consider that our method will become a
valuable tool in the systematic analysis of biological
pathways, and will help to extract more meaningful in-
formation from gene expression data.
Methods
To implement the method, a list of differential genes
and a list of background genes, both formatted with
gene identifier (e.g. gene symbol or RefSeq ID), is
required. A list of pathways and their topology, and a
means of mapping genes to pathway nodes, is also
required. In this study, 223 NCI-Nature pathways from
PID (released September 9th 2011) are included. The
pathway data are parsed from XML format file provided
by the PID FTP site. The Perl code for parsing can be
obtained from the author’s website (http://mcube.nju.
edu.cn/jwang/lab/soft/cepa/). The general workflow of
the method is illustrated in Figure 6.
Generate mapping data
PID provides mappings from UniProt ID to node id. In
this study, gene symbol is selected as the primary
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ID [50] (accomplished via the online “custom down-
loads” tool in HGNC database) and the mapping from
HGNC ID to UniProt ID [51] (using idmapping.dat.gz
on the UniProt FTP site) are first extracted. The final
mapping from gene symbol to node id is generated by
merging the above three kinds of mapping data.
Centrality measurements
Two commonly used centralities, degree and shortest path
betweenness, are selected as initial candidate measure-
ments. Degree centrality quantifies the number of neigh-
boring nodes to which the node of interest is directly
connected, while betweenness centrality measures the
amount of information streaming through a given node.
To measure the importance of nodes in the network from
multiple aspects, we defined an additional centrality: largest
reach. This centrality is based on the shortest path between
two nodes and the value of the centrality is affected by all
other nodes in the network. The largest reach centrality
measures how far a node can send or receive information.
It is defined as the largest length of the shortest path from
node v to all other nodes in the network (see Equations 3
and 4 where d(w, v) refers to the shortest path length be-
tween nodes v and w). In a directed network, this measure
is denoted as in-largest reach or out-largest reach.
Cinlr vð Þ ¼ maxw2V d w; vð Þf g ð3Þ
Coutlr vð Þ ¼ maxw2V d v;wð Þf g ð4Þ
Users of our system can replace the provided centrality
measures with their centrality measurements of interest.
It is recommended that centrality choice is guided by
biological plausibility and/or reality.
Pathway score
The score is defined as the summation of the weights of





di ¼ 1 differentially affected0 else

ð6Þ
where s is the score of the pathway, wi is the weight of
the ith node and reflects the importance of the node, n is
the number of nodes in the pathway, and di identifies
whether the ith node is differentially affected or not.
In our model, we weight the nodes by network central-
ity. Because the network centrality can be zero, an add-
itional term is added to the weight measure. In Equation
7, α is a small positive number to ensure that all weights




i ¼ wi þ α ð7Þ
Theoretical distribution of the pathway score
To calculate the theoretical distribution of the pathway
score, we assume that every node is a single gene and that
our model satisfies the following conditions: 1) genes are
independent; 2) w and d are random variables; 3) w and d
are independent; 4) w follows a particular discrete or con-
tinuous distribution and d is a Bernoulli random variable.
Thus the pathway score, denoted as S, is also a random
variable. These conditions are formally expressed as
wePw wð Þ ð8Þ
P d ¼ 1ð Þ ¼ 1 P d ¼ 0ð Þ ¼ pdiff ð9Þ
where pdiff is the probability that a gene is differentially
expressed. It is calculated as the proportion of differen-
tially expressed genes on the microarray.
pdiff ¼ ndiffnbg ð10Þ
Within a pathway of score s, assume that k differential
genes (d= 1) and n-k non-differential genes (d= 0) exist,
so that s can be written as
s ¼ w1 þ . . .þ wk þ 0kþ1 þ . . .þ 0n ð11Þ
Thus the probability that pathway score S is equal to
or larger than s is














The binomial term of equation 12 is the probability of
obtaining k differential genes from n genes, and the sec-
ond term is the probability that the sum of k differential
genes’ weight is equal to or larger than s. The final prob-
ability P(S≥ s) is the summation over all conditions of k.
Since genes are independent, provided that Pw(w) is
known, the distribution of the summation of w can be
calculated. For instance, given a pathway with ER ran-
dom network structure in which nodes are weighted by
degree, w will follow a binomial distribution and thus P
(Σiwi) also follows a binomial distribution.
Non-parametric null distribution of the pathway score
In applications, because the weight distribution is not easily
determined and nodes are not independent after the map-
ping procedure, the theoretic distribution is difficult to cal-
culate. A non-parametric null distribution of s can be
generated through simulation. For every gene in a pathway,
we guess whether it is differentially expressed. Similar to
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ity pdiff (calculated by Equation 10) of being differentially
expressed. In each simulation, we obtain a list of simulated
differentially expressed genes in the pathway. This simu-
lated differential gene list is then mapped to the pathway
nodes. The pathway structure is unchanged and the simu-
lated pathway score is re-calculated from Equations 5 and
6. The significance is calculated as the proportion of the
simulated score exceeding the real score (Equation 13).
p ¼ # ssimulate≥s =# simulationf g ð13Þ
Extension on GSA
The ORA centrality-based enrichment method yielded
plausible, biologically relevant results in the simulation
study and real-world data analysis. However, an oft-
mentioned drawback of ORA is that an objective cutoff is
appointed in the acquisition of a differential gene list, with
the following consequences: 1) The resulting pathway or
network may be sensitive to the cutoff [52]. In the
centrality-based extension of ORA, when a high-scoring
node is marginally close to the imposed cutoff, this effect
can be critical; 2) In some circumstances, differential genes
are too few to apply ORA [53]; 3) Binary transformation of
expression data leads to loss of information. To address
these issues, researchers have developed the GSA frame-
work, which utilizes all gene expression values. Like trad-
itional ORA however, GSA assumes that genes in pathways
occupy unvarying positions in the topological structure. We
propose that our centrality-based enrichment methodology
can be similarly extended on GSA. In this section, we sug-
gest, but do not implement, a conceptual methodological
extension to the GSA method.
In the traditional univariate GSA procedure, the score
s of the pathway is defined as:
s ¼ f gð Þ ð14Þ
where f transforms the gene-level statistic to a pathway-
level statistic (e.g. by summation, averaging) and g is the
gene-level statistic vector which typically comprises t-values
[6,10,52]. In ORA, g is a binary variant and f(g) is summa-
tion. In our model to extend GSA, gene-level statistic is first
transformed to node-level statistic. We define the vector of
the node-level statistics as d. When nodes in pathways com-
prise multiple genes, the node-level statistic can be consid-
ered as the maximum value of the corresponding member
genes. Using centrality as the weight, the score is defined as
s ¼ f w  dð Þ ð15Þ
where w is the weight vector and the transformation func-
tion f acts upon the product of w and d. Equation 15 incor-
porates centrality weight into the original node-level
statistic. To prevent w from overpowering d (or vice versa)
when both vectors contain continuous variables, wepropose that w and d should be normalized. The null distri-
bution of the pathway score could then be generated by per-
muting the gene expression matrix.
Implementation
The method proposed in the article has been implemen-
ted in an R package named CePa which is available at
CRAN (http://www.r-project.org/). In the CePa package,
four pathway catalogues, namely NCI-Nature, BioCarta,
Reactome and KEGG from PID, have been integrated.
Centrality calculation and network visualization are pro-
cessed by igraph package [54]. A web-based version of
CePa is available for researchers who are not familiar
with R programming (http://mcube.nju.edu.cn/cgi-bin/
cepa/main.pl), in which Cytoscape Web is used for net-
work visualization [55].
Additional files
Additional file 1: Two random pathways generated from ER model
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under different centrality measurements.
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